Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.42 |
| ▸ | FABP7 | O15540 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | MDM4 | O15151 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8351536 | 1.00 | FABP5 (0.42) | FABP5FABP7KMT2AEPHX2DPP8 | |
| SCHEMBL5157204 | 0.78 | FABP5 (0.54) | FABP5FABP7KMT2AEPHX2DPP8 | |
| SCHEMBL30510279 | 0.78 | FABP5 (0.54) | FABP5FABP7KMT2AEPHX2DPP8 | |
| SCHEMBL1830867 | 0.78 | FABP5 (0.54) | FABP5FABP7KMT2AEPHX2DPP8 | |
| SCHEMBL3576113 | 0.78 | FABP5 (0.54) | FABP5FABP7KMT2AEPHX2DPP8 | |
| SCHEMBL6558488 | 0.78 | FABP5 (0.54) | FABP5FABP7KMT2AEPHX2DPP8 | |
| SCHEMBL30510365 | 0.78 | FABP5 (0.54) | FABP5FABP7KMT2AEPHX2DPP8 | |
| SCHEMBL30510380 | 0.78 | FABP5 (0.54) | FABP5FABP7KMT2AEPHX2DPP8 | |
| SCHEMBL7147050 | 0.76 | FABP5 (0.45) | FABP5FABP7KMT2AEPHX2DPP8 | |
| SCHEMBL14393126 | 0.74 | FABP5 (0.46) | FABP5FABP7KMT2AEPHX2MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119823223-A | Apelin peptide energy macrocycle and application thereof | SOCPRA健康与人文科学有限公司 | 2025-04-15 | — | — | CN | claimed |
| EP-4448547-A1 | APELINERGIC MACROCYCLES AND USES THEREOF | Socpra Sciences Santé Et Humaines S.E.C. (CA) | 2024-10-23 | — | — | EP | claimed |
| CN-118829646-A | Apelin peptide energy macrocycle and application thereof | SOCPRA健康与人文科学有限公司 | 2024-10-22 | — | — | CN | claimed |
| US-20240343761-A1 | APELINERGIC MACROCYCLES AND USES THEREOF | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2024-10-17 | — | — | US | claimed |
| WO-2023108291-A9 | APELINERGIC MACROCYCLES AND USES THEREOF | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2023-09-28 | — | — | WO | claimed |
| WO-2023108291-A1 | APELINERGIC MACROCYCLES AND USES THEREOF | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2023-06-22 | — | — | WO | claimed |
| CN-119823223-A | Apelin peptide energy macrocycle and application thereof | SOCPRA健康与人文科学有限公司 | 2025-04-15 | — | — | CN | disclosed |
| EP-4448547-A1 | APELINERGIC MACROCYCLES AND USES THEREOF | Socpra Sciences Santé Et Humaines S.E.C. (CA) | 2024-10-23 | — | — | EP | disclosed |
| CN-118829646-A | Apelin peptide energy macrocycle and application thereof | SOCPRA健康与人文科学有限公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20240343761-A1 | APELINERGIC MACROCYCLES AND USES THEREOF | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2024-10-17 | — | — | US | disclosed |
| WO-2024011333-A1 | METHOD OF TREATING SKELETAL MUSCLE STEM CELL PATHOLOGIC DYSFUNCTION | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2024-01-18 | — | — | WO | disclosed |
| WO-2023108291-A9 | APELINERGIC MACROCYCLES AND USES THEREOF | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023108291-A1 | APELINERGIC MACROCYCLES AND USES THEREOF | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343761-A1 | APELINERGIC MACROCYCLES AND USES THEREOF | APLNR, AP3D1, AP3B1 | FABP5 1240/4885FABP7 336/4885KMT2A 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.